Annonce • Jun 21
Lannett Company, Inc. Files Form 15 Lannett Company, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.001per share. Reported Earnings • Feb 03
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2023 results: US$0.88 loss per share (improved from US$2.01 loss in 2Q 2022). Revenue: US$80.9m (down 6.5% from 2Q 2022). Net loss: US$36.3m (loss narrowed 55% from 2Q 2022). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) missed analyst estimates by 110%. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings. Annonce • Jan 26
Lannett Company, Inc. to Report Q2, 2023 Results on Feb 01, 2023 Lannett Company, Inc. announced that they will report Q2, 2023 results After-Market on Feb 01, 2023 Annonce • Jan 05
Lannett Company Provides Development Update on Biosimilar Insulin Products On January 4, 2023, Lannett Company, Inc. provided an update on the clinical advancement and development of its biosimilar insulin aspart and biosimilar insulin glargine products. Lannett is developing both products with its strategic alliance partner, the HEC Group of companies (HEC). The company said results from the study of Lannett/HEC biosimilar insulin aspart versus US NovoLog® (the reference biologic) indicated the products were highly comparable when animals were dosed with equal quantities of the drugs via subcutaneous route. Data from the study will be submitted to the FDA as part of the company's request, expected in the first half of calendar 2023, for a Biosimilar Biological Product Development (BPD) Type II meeting. The company also said that analysis of the pivotal trial results for its biosimilar insulin glargine continues, though it now anticipates top-line data to be available by the end of February 2023. Annonce • Nov 30
Lannett Company, Inc., Annual General Meeting, Jan 25, 2023 Lannett Company, Inc., Annual General Meeting, Jan 25, 2023, at 09:00 US Eastern Standard Time. Location: 1150 Northbrook Drive Trevose, PA 19053 Trevose Pennsylvania United States Agenda: To elect five (5) members of the board of directors (the “board”) to serve until the next annual meeting of stockholders; to ratify the selection of grant thornton, llp as independent auditors for the fiscal year ending june 30, 2023; to obtain a non-binding advisory vote on the compensation of the company’s executive officers; to approve a proposed amendment to Certificate of Incorporation (the “Certificate of Incorporation”); to approve one or more adjournments of the Annual Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to approve the Reverse Stock Split proposal at the time of the Annual Meeting or in the absence of a quorum; and to transact such other business as may properly come before the annual meeting or any adjournment thereof. Price Target Changed • Nov 16
Price target decreased to US$1.00 Down from US$2.25, the current price target is provided by 1 analyst. New target price is 96% above last closing price of US$0.51. Stock is down 74% over the past year. The company is forecast to post a net loss per share of US$1.47 next year compared to a net loss per share of US$5.74 last year. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Melissa Rewolinski was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 04
First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2023 results: US$0.68 loss per share (further deteriorated from US$0.56 loss in 1Q 2022). Revenue: US$75.1m (down 26% from 1Q 2022). Net loss: US$28.0m (loss widened 25% from 1Q 2022). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) missed analyst estimates by 51%. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 2 percentage points per year. Major Estimate Revision • Sep 01
Consensus revenue estimates fall by 16% The consensus outlook for revenues in 2023 has deteriorated. 2023 revenue forecast decreased from US$344.0m to US$288.9m. Forecast losses increased from -US$1.39 to -US$1.54 per share. Pharmaceuticals industry in the US expected to see average net income growth of 0.1% next year. Consensus price target down from US$2.25 to US$1.00. Share price fell 14% to US$0.49 over the past week. Reported Earnings • Aug 25
Full year 2022 earnings: EPS misses analyst expectations Full year 2022 results: US$5.74 loss per share (up from US$9.23 loss in FY 2021). Revenue: US$340.6m (down 29% from FY 2021). Net loss: US$231.6m (loss narrowed 36% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 230%. Over the next year, revenue is forecast to grow 1.0%, compared to a 25% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings. Board Change • Aug 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Melissa Rewolinski was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 06
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Third quarter 2022 results: US$0.86 loss per share (down from US$0.18 loss in 3Q 2021). Revenue: US$78.4m (down 30% from 3Q 2021). Net loss: US$34.9m (loss widened 389% from 3Q 2021). Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) also missed analyst estimates by 110%. Over the next year, revenue is expected to shrink by 7.1% compared to a 7.6% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has fallen by 57% per year, which means it is performing significantly worse than earnings. Price Target Changed • Apr 27
Price target decreased to US$3.00 Down from US$5.00, the current price target is an average from 2 analysts. New target price is 414% above last closing price of US$0.58. Stock is down 88% over the past year. The company is forecast to post a net loss per share of US$1.74 next year compared to a net loss per share of US$9.23 last year. Reported Earnings • Feb 05
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2022 results: US$2.01 loss per share (up from US$4.36 loss in 2Q 2021). Revenue: US$86.5m (down 35% from 2Q 2021). Net loss: US$81.1m (loss narrowed 53% from 2Q 2021). Revenue missed analyst estimates by 4.1%. Earnings per share (EPS) exceeded analyst estimates by 474%. Over the next year, revenue is expected to shrink by 1.1% compared to a 19% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings. Recent Insider Transactions • Dec 04
Non-Executive Independent Chairman recently bought US$86k worth of stock On the 29th of November, Patrick LePore bought around 50k shares on-market at roughly US$1.71 per share. This was the largest purchase by an insider in the last 3 months. Patrick has been a buyer over the last 12 months, purchasing a net total of US$235k worth in shares. Reported Earnings • Nov 05
First quarter 2022 earnings released: US$0.56 loss per share (vs US$0.17 loss in 1Q 2021) The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2022 results: Revenue: US$101.5m (down 20% from 1Q 2021). Net loss: US$22.3m (loss widened 244% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings. Price Target Changed • Nov 05
Price target decreased to US$5.00 Down from US$6.00, the current price target is an average from 2 analysts. New target price is 116% above last closing price of US$2.32. Stock is down 61% over the past year. The company is forecast to post a net loss per share of US$1.32 next year compared to a net loss per share of US$9.23 last year. Recent Insider Transactions • Sep 14
Independent Director recently sold US$81k worth of stock On the 9th of September, Melissa Rewolinski sold around 25k shares on-market at roughly US$3.18 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$90k more than they bought in the last 12 months. Recent Insider Transactions Derivative • Sep 13
Independent Director notifies of intention to sell stock Melissa Rewolinski intends to sell 25k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of September. If the sale is conducted around the recent share price of US$3.18, it would amount to US$81k. Since December 2020, Melissa's direct individual holding has increased from 44.77k shares to 87.44k. Company insiders have collectively sold US$9.8k more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Aug 27
Full year 2021 earnings released: US$9.23 loss per share (vs US$0.86 loss in FY 2020) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: US$478.8m (down 12% from FY 2020). Net loss: US$363.5m (loss widened US$330.1m from FY 2020). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings. Price Target Changed • Aug 26
Price target increased to US$7.00 Up from US$5.88, the current price target is an average from 3 analysts. New target price is 86% above last closing price of US$3.77. Stock is down 27% over the past year. Board Change • Aug 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Melissa Rewolinski was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • May 14
Non-Executive Independent Chairman recently bought US$84k worth of stock On the 11th of May, Patrick LePore bought around 20k shares on-market at roughly US$4.18 per share. This was the largest purchase by an insider in the last 3 months. This was Patrick's only on-market trade for the last 12 months. Price Target Changed • May 12
Price target decreased to US$5.88 Down from US$6.38, the current price target is an average from 5 analysts. New target price is 41% above last closing price of US$4.17. Stock is down 44% over the past year. Reported Earnings • May 07
Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.43 loss in 3Q 2020) The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2021 results: Revenue: US$112.4m (down 22% from 3Q 2020). Net loss: US$7.14m (loss narrowed 57% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings. Is New 90 Day High Low • Feb 24
New 90-day low: US$5.93 The company is down 6.0% from its price of US$6.28 on 25 November 2020. The American market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$25.11 per share. Recent Insider Transactions • Feb 11
Independent Director recently sold US$203k worth of stock On the 8th of February, David Drabik sold around 33k shares on-market at roughly US$6.08 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$700k more than they bought in the last 12 months. Reported Earnings • Feb 05
Second quarter 2021 earnings released: US$4.36 loss per share (vs US$0.13 profit in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2021 results: Revenue: US$133.9m (down 1.6% from 2Q 2020). Net loss: US$171.9m (down US$177.0m from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings. Analyst Estimate Surprise Post Earnings • Feb 05
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 8,620%. Over the next year, revenue is forecast to grow 1.1%, compared to a 31% growth forecast for the Pharmaceuticals industry in the US. Is New 90 Day High Low • Jan 26
New 90-day high: US$7.93 The company is up 19% from its price of US$6.67 on 27 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$33.65 per share. Reported Earnings • Nov 06
First quarter 2021 earnings released: US$0.17 loss per share The company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were flat. First quarter 2021 results: Revenue: US$126.5m (flat on 1Q 2020). Net loss: US$6.50m (loss narrowed 47% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings. Analyst Estimate Surprise Post Earnings • Nov 06
Revenue and earnings miss expectations Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to stay flat compared to a 31% growth forecast for the Pharmaceuticals industry in the US. Price Target Changed • Oct 15
Price target lowered to US$7.75 Down from US$9.75, the current price target is an average from 5 analysts. The new target price is 16% above the current share price of US$6.66. As of last close, the stock is down 44% over the past year. 